Elanco Animal Health, Mattenstrasse 24a, 4058, Basel, Switzerland.
Elanco Animal Health, 2500 Innovation Way, Greenfield, IN, 46140, USA.
Parasit Vectors. 2017 Nov 1;10(1):526. doi: 10.1186/s13071-017-2479-8.
Lotilaner is a novel isoxazoline developed for oral administration to dogs. In laboratory studies, lotilaner was shown to be safe and to produce a rapid flea and tick knockdown, with a sustained speed of kill for at least a month post-treatment. A study was undertaken to demonstrate the efficacy, safety and palatability of three monthly doses of lotilaner flavoured chewable tablets (Credelio™, Elanco) in controlling fleas under field conditions in Europe.
Dogs were enrolled at 17 veterinary clinics across Germany, Hungary and Portugal. Qualifying households having no more than three dogs and one primary dog with at least five fleas was randomised 2:1 to a lotilaner (minimum dose rate 20 mg/kg) or a topical fipronil group (administered per label). There were 128 and 64 households allocated to the lotilaner and fipronil groups, respectively. Treatments were dispensed to owners on Days 0, 28 and 56; supplementary household dogs received the same treatment as the primary dog. Post-enrollment flea counts and flea allergy dermatitis (FAD) assessments were made on primary dogs on Days 14, 28, 56 and 84. Efficacy calculations were based on geometric mean percent reductions of live flea counts versus pre-treatment counts on Day 0. The safety and palatability of lotilaner tablets were also assessed.
Lotilaner efficacy was 99.1, 99.5, 99.9 and 99.8% on Days 14, 28, 56 and 84, respectively. Corresponding reductions for fipronil were 93.4, 91.2, 94.4 and 97.0%. Lotilaner was superior to fipronil at all post-Day 0 assessments (t ≥ 3.43, P ≤ 0.0007). At every post-treatment assessment, at least 90% of lotilaner-treated dogs were flea-free (98.4% on Day 84); fewer than 90% of fipronil group dogs were flea-free on the same time points. Lotilaner flavoured chewable tablets were palatable, and both products were well tolerated. Lotilaner alleviated or eliminated clinical signs of FAD, including pruritus.
Under field conditions in Europe, lotilaner flavoured chewable tablets were greater than 99% effective in eliminating fleas from dogs at the first post-treatment assessment (Day 14). Efficacy was maintained through Day 84, with corresponding improvements in FAD. Lotilaner tablets were palatable and safe and provided superior flea control to fipronil.
Lotilaner 是一种新型的异噁唑啉类药物，专为犬类口服而开发。在实验室研究中，Lotilaner 被证明是安全的，并能迅速击倒跳蚤和蜱虫，至少在治疗后一个月内保持持续的杀灭速度。一项研究旨在证明在欧洲野外条件下，三种每月剂量的 Lotilaner 调味咀嚼片（Elanco 的 Credelio）在控制跳蚤方面的疗效、安全性和适口性。
在德国、匈牙利和葡萄牙的 17 家兽医诊所招募了犬只。符合条件的家庭最多有三只狗，且只有一只主要的狗有至少 5 只跳蚤，这些家庭被随机分为 2:1 的 Lotilaner（最低剂量率 20mg/kg）或局部用氟虫腈组。Lotilaner 组和氟虫腈组分别有 128 户和 64 户家庭。在第 0、28 和 56 天，将药物分发给主人；主要犬的辅助家庭犬接受与主要犬相同的治疗。在第 14、28、56 和 84 天，对主要犬进行跳蚤计数和跳蚤过敏性皮炎（FAD）评估。疗效计算基于第 0 天活跳蚤计数相对于治疗前计数的几何平均百分比减少。还评估了 Lotilaner 片剂的安全性和适口性。
Lotilaner 的疗效分别为第 14、28、56 和 84 天的 99.1%、99.5%、99.9%和 99.8%，氟虫腈的疗效分别为 93.4%、91.2%、94.4%和 97.0%。Lotilaner 在所有第 0 天以后的评估中均优于氟虫腈（t≥3.43，P≤0.0007）。在每次治疗后评估中，至少 90%的 Lotilaner 治疗犬无跳蚤（第 84 天为 98.4%）；氟虫腈组在同一时间点，不到 90%的犬无跳蚤。Lotilaner 调味咀嚼片适口性好，两种产品均耐受良好。Lotilaner 缓解或消除了 FAD 的临床症状，包括瘙痒。
在欧洲野外条件下，Lotilaner 调味咀嚼片在第一次治疗后（第 14 天）对狗的跳蚤消除率超过 99%。疗效一直持续到第 84 天，同时 FAD 也得到了改善。Lotilaner 片剂适口性好，安全性高，跳蚤控制效果优于氟虫腈。
